Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 30 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

23%

7 trials in Phase 3/4

Results Transparency

0%

0 of 14 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

15Total
Not Applicable (3)
Early P 1 (2)
P 1 (2)
P 2 (1)
P 3 (3)
P 4 (4)

Trial Status

Completed14
Unknown8
Recruiting4
Withdrawn2
Active Not Recruiting1
Suspended1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 14 completed trials

Clinical Trials (30)

Showing 20 of 20 trials
NCT05632315Phase 2Active Not Recruiting

PMT for MDRO Decolonization

NCT04759001Phase 1RecruitingPrimary

FMT for the Decolonization of Carbapenem-resistant Enterobacteriaceae

NCT05055479CompletedPrimary

Nosocomial Outbreak of BHRe in an Intensive Care Unit During SARS-CoV-2 Pandemic

NCT07172932Completed

ANTIBIOTIC-RESISTANT ENTEROBACTERALES BLOODSTREAM INFECTIONS AND RISK FACTORS IN PATIENTS ADMITTED TO THE INTENSIVE CARE UNIT

NCT03671967Phase 4Recruiting

PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)

NCT05355350Phase 4Withdrawn

PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections

NCT03924934CompletedPrimary

Community-associated Highly-Resistant Enterobacterales

NCT05035342Phase 3RecruitingPrimary

Fecal Transplantation to Eradicate Colonizing Emergent Superbugs

NCT05791396Phase 1RecruitingPrimary

FMT to Eradicate Intestinal Colonization by Carbapenem-resistant Enterobacteriaceae

NCT03891433Phase 4Suspended

Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae

NCT04276480Not ApplicableCompletedPrimary

Efficacy of Piperacillin-tazobactam as Empirical Antimicrobial Therapy for VAP Among ESBL-E Carriers.

NCT05516433UnknownPrimary

Effect of Imipenem and Meropenem on the Digestive Microbiota and the Emergence and Carriage of Multidrug-resistant Bacteria

NCT04836208UnknownPrimary

Neonatal Acquisition of ESBL-PE in a Low-income Country - NeoLIC

NCT02482051Completed

Ultra Rapid Culture Independent Detection of High-Priority Carbapenem Resistant Enterobacteriaceae Directly From Blood

NCT03477084Completed

Understanding and Modeling Reservoirs, Vehicles and Transmission of ESBL-producing Enterobacteriaceae in the Community and Long Term Care Facilities

NCT04903886Unknown

Intensive Care Unit Acquired Infections in Patients Colonized With Extended Spectrum Enterobacteriaceae

NCT04528043Completed

Infections and Colonization With the Third Group of Enterobacteriaceae in the Intensive Care Unit

NCT02795949Phase 3CompletedPrimary

Study on Reduced Antibiotic Treatment vs Broad Spectrum Betalactam in Patients With Bacteremia by Enterobacteriaceae

NCT03527056Early Phase 1WithdrawnPrimary

Pilot Study Using Oral Capsule FMT to Decolonize GI CRE

NCT03967301Not ApplicableUnknown

Prevention and Decolonization of Multidrug-resistant Bacteria With Probiotics

Scroll to load more

Research Network

Activity Timeline